Loading...

Follow ScienceDaily | Mesothelioma News on Feedspot

Continue with Google
Continue with Facebook
or

Valid
A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to new results.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Investigators have found that combined treatment with two cancer immunotherapy drugs -- one a novel immune modulator and one that focuses and activates the anti-tumor immune response -- significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview